Wellteq Digital Health Inc. Improves Nightly Sleep by 38 Minutes for Employees Across 13 Countries Study Published in US Medical Journal

Wellteq Digital Health Inc. Improves Nightly Sleep by 38 Minutes for Employees Across 13 Countries Study Published in US Medical Journal

  • WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has deployed the Company's sleep program in partnership with WTW (NASDAQ:WTW) to improve the sleep of employees within a large financial institution with operations in over 13 countries.

  • The Wellteq sleep program resulted in an improvement in sleep duration of an average of 38 minutes per night, as published in the Journal of Community Medicine & Public Health Care in the United States1.

  • McKinsey estimates that the cost of sleep deprivation towards burnout, exhaustion and depression is $680 billion per year in just five OECD countries, in the U.S. alone, 70M people are plagued with chronic insomnia2 (McKinsey, 2021).

  • Wellteq offers its corporate and insurance customers digital solutions across the four pillars of wellbeing - activity, nutrition, mental health and sleep. These evidence-based solutions are generating health outcomes and journal publications from the sub-clinical domain as the Company advances its digital solutions toward clinical settings.

  • Digital Health is a fast-growing market with projected CAGR of 25% to reach $660 billion by 20253 (Statistica, 2021).

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) (the "Company" or Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce the publication of "The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia" in the Journal of Community Medicine & Public Health Care published in the United States. The article was co-authored by WTW (NASDAQ:WTW) Regional Senior Consultant of Workplace Health and Wellbeing, Ms. Pheona Chua.

The results were drawn from across 13 nations, 8 enterprise markets and 529 participants and demonstrate a substantial and clinically meaningful improvement in nightly sleep duration achieved by 59% of employee participants. The weighted average sleep duration increase was 38 minutes of nightly additional sleep achieved. Based on an initial average sleep duration of 7 hours, this represents a 9% increase in weighted average nightly sleep duration. To view the study, visit:

https://www.heraldopenaccess.us/openaccess/the-hidden-public-health-problem-of-inadequate-sleep-deploying-digital-mobile-technology-to-improve-employee-sleep-hygiene-in-asia

Senior Consultant, Corporate Health & Wellbeing, Asia, WTW, Ms Pheona Chua shares "A benefit trends survey we conducted recently shows that two-thirds of employers in Asia Pacific are greatly concerned about employee stress, burnout and mental health issues - it is by far the leading concern they have for their workforce. One way to support employees is to help them have better quality and quantity of sleep. Multiple research has shown that sleep deprivation significantly affects our health, work performance, safety and overall wellbeing4. It is therefore beneficial that employers find ways to support employees in prioritising quality sleep in their daily lives so that they can perform their best at work. These do not need to be sophisticated. A simple sleep campaign can help employees to improve their sleeping habits. The focus here is to protect employees' wellbeing in whatever ways it takes".

Wellteq Medical Advisor and lead author Dr George Gellert stated, "The study findings demonstrate empirically and validate the ability of Wellteq's technology platform to effectively engage employees, and help them make the behavioral changes needed to reduce the contribution of inadequate sleep duration and hygiene to poor physical and mental health, and to inferior work performance and low job satisfaction. This sleep wellness capability5 will be integrated seamlessly with remote sleep monitoring and telemedicine capabilities the Company will release to market in 2022, enabling Wellteq to provide an unparalleled comprehensive sleep health solution to employers, providers and payers. In addition, the B2B and strategic partnering opportunities with existing manufacturers of sleep apnea and related sleep disorder technology will positively disrupt the current market, greatly benefiting employees and patients, and those who seek to maximize their health and well-being."

Wellteq CEO, Scott Montgomery states, "Sleep sits upstream to having the clarity and energy to make other lifestyle changes around mindset, then diet and exercise. It is hard for anyone to get their head right and to get their body right if they are not sleeping well. We are delighted to see Wellteq's sleep program and technological capabilities achieve these outcomes across large employee populations in multiple countries. In 2021, we began and in 2022 will continue a focus on expanding our existing mobile capabilities into telemedical health improvement and wellness across the full lifecycle of health care, health promotion and disease prevention. This will differentiate us in the corporate wellness marketplace and builds on our 2021 initiatives and momentum."

The impact of poor sleep hygiene on employee performance is costly for employers and insurers. Inadequate sleep and/or disrupted sleep are also one of the modifiable predictors of and contributors to chronic health problems among employees, generating significant avoidable costs for employers. Sleep impacts mental health, incidence of fatigue, burnout and exhaustion, and decreases workplace productivity by $1,300 to $3,000 per employee2. Work-from-home (WFH) has also created conditions that make the identification of employees at risk or suffering from these conditions much more difficult for management teams and colleagues, as well as far more challenging to support and remediate.

The future of sleep health and hygiene management is rapidly integrating digital tools and home-based solutions in a full lifecycle continuum with workplace efforts. Wellteq is positioned at the forefront of sleep disorder diagnosis, management and wellness coaching through its technology evolution and recent partnership with Monash University, a globally leading research and care delivery institution. Wellteq's ability to assess and achieve better sleep among large employee populations through a scalable digital platform is a key contributor to the Company's growth. Revenue from the global sleep market is projected to reach USD $137 billion by 2026, presenting a substantial and compelling opportunity for digital sleep health and wellness solution providers6.

References

  1. https://www.heraldopenaccess.us/openaccess/the-hidden-public-health-problem-of-inadequate-sleep-deploying-digital-mobile-technology-to-improve-employee-sleep-hygiene-in-asia
  2. https://www.mckinsey.com/industries/life-sciences/our-insights/sleep-on-it-addressing-the-sleep-loss-epidemic-through-technology
  3. https://www.statista.com/statistics/1092869/global-digital-health-market-size-forecast/
  4. https://www.wtwco.com/en-SG/Insights/2022/01/a-purposeful-employee-experience-is-driving-asia-pacific-employers-benefit-strategies
  5. https://www.businesswire.com/news/home/20211026005728/en/Wellteq-Digital-Health-Inc.-Partners-With-Top-Global-University-to-Commercialise-Sleep-Research
  6. https://www.arizton.com/market-reports/sleep-market-size-analysis

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success-and provide perspective that moves you. Learn more at wtwco.com.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading global provider of personalized digital health and wellness solutions across the continuum of care. To learn more, visit https://www.wellteq.co.

Download the Wellteq Corporate Presentation: https://wellteq.co/about/investors/

Wellteq Investor Contact:
 
Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113128

News Provided by Newsfile via QuoteMedia

WTEQ:CC
The Conversation (0)
wellteq Digital Health Inc. Announces Health Insurer Partner Extends the wellteq Digital Health Solution to All Australians

wellteq Digital Health Inc. Announces Health Insurer Partner Extends the wellteq Digital Health Solution to All Australians

  • nib (ASX: NHF) extends wellteq's digital health solutions to all Australians through the launch of GreenPass.

  • wellteq's digital health solution integrates its preferred partners, including Garmin (NASDAQ: GRMN) and other health provider partners, into the nib-customised digital wellness app to deliver several benefit pathways, from online health assessments, personalised content and rewards to expanding virtual care services.
  • Digital health is projected to be a USD 295.4 billion industry by 2028 with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028.
  • Asia-Pacific (APAC) is expected to register the fastest CAGR over the forecast period due to the rising usage of tablets, smartphones, and other mobile platforms across the region, which includes Australia, Japan, China, India, South Korea and Singapore.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or "wellteq"), is pleased to announce that one of Australia's largest health insurers, nib holdings limited (ASX: NHF), will now offer wellteq's digital health solution to all Australians, a population of over 25 million people.

nib Group (nib) is a trusted international health partner with over one million members across Australia. The launch of nib's GreenPass membership provides Australians with access to a range of exclusive health and wellness benefits without the need to take out a traditional health insurance product. The subscription-based service aims to empower more people to put their health and wellbeing first. Read more from nib's press release:

https://www.nib.com.au/media/2022/04/media-pages-nib-launches-unique-greenpass-health-membership

wellteq's digital health solution integrates its partners, including Garmin, Fitbit, Apple, and other health provider partners, into the nib-customised digital wellness app to help them deliver personalised content and healthy action nudges, gamification, rewards and more. nib's GreenPass membership enables non-private health insurance members to access several different benefit pathways, from personalised health plans, discounts on health and wellness services, rewards for reaching health goals through their well with nib app, an online skin check, fitness tracking and exclusive pricing with nib's network of trusted health professionals.

wellteq Chief Operating Officer, Jeames Gillett said: "wellteq has been working closely with nib for several years to evolve our shared ambition of providing personalised health and wellbeing at scale. We're incredibly excited to support nib in the launch of GreenPass as it extends access beyond private health insurance members to the wider Australian population. At a time when our health and wellbeing has been tested, access to GreenPass will provide individuals with an opportunity to have personalised support on their journey to better health."

Ed Close, nib Chief Executive Australian Residents Health Insurance said: "the GreenPass is a game-changer for the industry, designed to help more Aussies access the right tools, services and information they need to support their better health."

"By making membership as much about supporting good health as the treatment of sickness and injury we have an opportunity to play a bigger role in how we help more Australians to keep healthy and out of hospital,"

"With this in mind, we created nib GreenPass, which is intentionally created to empower people of all ages to better understand their health profile and offer health and wellness perks and services they can use every day to keep on top of their health."

This timely solution aligns with market projections1 that the global digital health industry will reach USD 295.4 billion by 2028, with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028. Asia-Pacific (APAC) is expected to register the fastest CAGR over the forecast period due to the rising usage of tablets, smartphones, and other mobile platforms across the region, which includes Australia, Japan, China, India, South Korea and Singapore.

Scott Montgomery, wellteq's Chief Executive Officer said: "when two companies missions align the synergies can create powerful things. nib's payer to partner strategy dovetails perfectly with wellteq's mission to coach healthier habits across the full continuum of healthcare. The manifestation of this synergy is GreenPass, a fantastic opportunity for anyone to try digital health tools at no cost and hopefully inspire them on a behaviour change journey that's good for them, good for nib and good for wellteq. The ideal win-win situation and another step towards proactive, equitable virtual care."

References

1. Digital Health Market Size, Share & Trends Analysis Report by Technology (Healthcare Analytics, mHealth), By Component (Software, Services), By Region, And Segment Forecasts, 2021 - 2028.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading global provider of personalized digital health and wellness solutions across the continuum of care. To learn more, visit https://wellteq.co/

Download the wellteq Corporate Presentation:

https://wellteq.co/about/investors/

wellteq Investor Contact:  
Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Digital Health Inc. Announces Release of the IoMT HealthHub

Wellteq Digital Health Inc. Announces Release of the IoMT HealthHub

  • WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has released the Company's internet of medical things (IoMT) HealthHub into device integrations with Beta research partners for testing purposes.
  • The wellteq HealthHub is the result of an extensive internal development effort to produce an open standard and scalable IoMT platform for distributed virtual care deployments in enterprise health, clinic, pharmacy, and remote locations.
  • The wellteq HealthHub connects, manages, and monitors both standardized medical and non-medical devices for a completely integrated IoMT/IoT intelligent edge solution, allowing for control of any standardized commercial, industrial, residential, or medical smart device - an industry first and must-have for next generation virtual care deployments.
  • The initial market for the wellteq HealthHub will be B2B for both in-market and new-to-market virtual care solutions.
  • wellteq will soon offer its baseline B2B virtual care platform integrating the wellteq HealthHub, wellteq Clinical Vitals Wearable and the wellteq Virtual Care Coaching APP.
  • The IoMT market is projected to grow from $30.79 billion in 2021 to $187.60 billion in 2028 at a compound annual growth rate (CAGR) of 29.5%1. While annual digital health spending is projected to reach $660 billion by 20252.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 32 countries is pleased to announce the Beta release of its new internet of medical things (IoMT) HealthHub, targeting commercial release later this year.

Based on a survey2of physicians in the United States who serve predominantly Medicare fee-for-service (FFS) and Medicare Advantage (MA) patients, McKinsey estimates that up to $265 billion (about $820 per person in the US) worth of care services - which represents up to 25% of the total cost of care - for Medicare FFS and MA beneficiaries could shift from traditional facilities to the home by 2025, without a reduction in quality or access.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Digital Health Inc. Launches North America Growth Division

Wellteq Digital Health Inc. Launches North America Growth Division

  • wellteq has appointed Mr Andrew Hvzid as Head of Growth, North America.
  • Based out of Toronto, Canada, Andrew Hvzid will be instrumental in accelerating wellteq's market share within the Corporate Wellness, Insurance and Health Provider sectors of Canada and North America, as well as leveraging the Company's existing distribution partners WTW (NASDAQ: WTW) and Garmin (NASDAQ: GRMN) in these new territories.
  • Mr Hvzid brings over a decade of executive experience in building strategic partnerships, identifying revenue-generating opportunities and optimising resources to propel growth across the health, fitness and education sectors.
  • Digital health is projected to be a USD 295.4 billion industry by 2028 with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028.
  • In 2020, North America accounted for the largest market share of the digital health industry at 38.77% and is expected to experience a steady CAGR over the forecast period.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or "wellteq"), is pleased to announce its strategic expansion into North America through the appointment of Mr. Andrew Hvizd as Head of Growth (NA) for the region. The Company recognises the importance of acquiring, developing and retaining top talent to drive commercial growth in the diverse and localised areas of the global digital health market - an industry that is projected to be valued at USD 295.4 billion by 2028[1].

As Head of Growth (NA), Andrew Hvizd will lead wellteq's go-to-market strategy in Canada and North America, enabling the Company's continued market expansion in the region. He will be instrumental in acquiring strategic partnerships and accelerating sustainable revenue growth, as well as leveraging wellteq's existing distribution partners, including WTW (NASDAQ: WTW) and Garmin (NASDAQ: GRMN), in these new territories.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Chairman Appointed to the Order of Canada for Leadership in Digital Health

Wellteq Chairman Appointed to the Order of Canada for Leadership in Digital Health

  • Dr. Peter W. Vaughan, CM, CD, MA, MD, MPH, ICD.D, Chairman of the Board of Directors at WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has been appointed to the Order of Canada.
  • Recognised by the Governor General of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health"
  • Digital Health market size projected at nearly 25% CAGR from 2019 to become a US$660 billion industry by 2025 (Statistica Research - July 2021)

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCBB: WTEQF), (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce the Company's Chairman, Dr Peter Vaughan, has been appointed to the Order of Canada by the Governor General of Canada.

The Governor General cited the appointment of Dr Vaughan "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
continuum global solutions

Wellteq Digital Health Inc. Upcoming Investor Events

  • WellteQ Digital Health Inc. (CSE: WTEQ / OTCQB: WTEQF)   is pleased to announce two upcoming investor events.
  • Wellteq will be hosting an Investor Webcast on November 10 th , 2021.
  • Wellteq will also be participating in the 3 rd Annual Canaccord Genuity Health & Wellness Conference on November 16 th , 2021

WellteQ Digital Health Inc.   (CSE: WTEQ) (OTCQB: WTEQF) , (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce two upcoming investor events.

Wellteq Investor Webcast on Wednesday, November 10th, 2021

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA ®   as the First Potential Treatment tor IgG4-RD

Phase 4 AGILE Data Support Shortening KRYSTEXXA ® Infusion Time

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets under management (AUM). Data was sourced from ETFdb.com on November 13, 2024, and all data was current as of that time.

Keep reading...Show less
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

PRISM MarketView a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. ( NASDAQ: CRDL, TSX: CRDL ) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRxâ„¢, positions it as a pioneer in addressing major unmet needs in cardiac care.

The US FDA has granted Orphan Drug Designation to CardiolRxâ„¢ for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol's MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. The MAVERIC-2 trial will evaluate the impact of CardiolRxâ„¢ in recurrent pericarditis patients following the cessation of interleukin-1 blocker therapy. MAVERIC-2 is expected to initiate in Q4 2024 at major pericardial disease centers across the United States and Europe, with results anticipated ahead of the company's planned pivotal Phase III MAVERIC-3 trial.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

"As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday Nov. 13, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE ® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the known profile of the medicine.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×